Lyka Labs Limited (LYKALABS) AI Stock Analysis

• Market Cap: ₹3.46B
• Dividend Yield: N/A
• Average Volume (3M): 1.93K
• Price to Earnings (P/E): 45.1
• Beta (1Y): 1.03
• Revenue Growth: 19.40%
• EPS Growth: 1286.88%
• Country: IN
• Employees: 423
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.26
• Shares Outstanding: 35,690,000
• 10 Day Avg. Volume: 958
• 30 Day Avg. Volume: 1,934
• PEG Ratio: -0.12
• Price to Book (P/B): 3.58
• Price to Sales (P/S): 2.64
• P/FCF Ratio: -26.96
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 58 Neutral
• Price Target: ₹99.00 ▲(4.87% Upside)

Lyka Labs Limited's stock score is primarily influenced by its financial performance, which shows strong revenue growth and operational efficiency. However, high liabilities and negative free cash flow pose risks. The technical analysis indicates a bearish trend, and the valuation suggests the stock is overvalued. The absence of earnings call data and corporate events limits additional insights.

Lyka Labs Limited Business Overview & Revenue Model

Company Description

Lyka Labs Limited (LYKALABS) is an innovative biotechnology company focused on the development and commercialization of advanced wellness and health solutions. The company operates primarily in the health and wellness sector, specializing in the formulation of nutritional supplements, functional foods, and personalized health products. Lyka Labs leverages cutting-edge research to create products that cater to the growing demand for health-conscious consumers seeking natural and effective solutions to enhance their well-being.

How the Company Makes Money

Lyka Labs generates revenue through multiple streams including the direct sale of its health and wellness products via online platforms and retail partnerships. The company has established a subscription model that allows customers to receive regular shipments of their products, providing a stable and recurring income. Additionally, Lyka Labs may engage in partnerships with health professionals and wellness influencers to promote its offerings, further driving sales through collaborative marketing efforts. The company's focus on research and development also positions it to explore licensing opportunities for its proprietary formulations, potentially contributing to its earnings.

Lyka Labs Limited Financial Statement Overview

Summary

Lyka Labs Limited shows strong revenue growth and improved operational efficiency with better EBIT and EBITDA margins. The balance sheet has strengthened with increased equity and reduced leverage, though high liabilities pose risks. Cash flow management is challenging, with negative free cash flow affecting flexibility.

Income Statement

Lyka Labs Limited has shown strong revenue growth, with a significant increase in Total Revenue from the previous years. The Gross Profit Margin is robust, indicating effective cost management. However, the Net Profit Margin has fluctuated, suggesting varying profitability levels. The EBIT and EBITDA margins have improved, reflecting enhanced operational efficiency over time.

Balance Sheet

The company has improved its financial position with increasing Stockholders' Equity, which has strengthened the Equity Ratio. The Debt-to-Equity Ratio has decreased, indicating reduced leverage. However, the overall liabilities remain high, posing potential financial risks. Return on Equity has improved due to better profitability in recent periods.

Cash Flow

Operating Cash Flow has been relatively stable but remains low compared to Net Income, indicating less cash generation from operations. Free Cash Flow has been negative, primarily due to high capital expenditures. The Free Cash Flow to Net Income ratio highlights challenges in converting profits into free cash flow, which could affect future investments.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.42B	1.41B	1.05B	916.90M	1.84B	671.07M
Gross Profit	853.99M	851.35M	599.41M	152.84M	1.30B	289.23M
EBITDA	204.94M	201.67M	167.59M	128.47M	1.01B	201.17M
Net Income	75.09M	80.12M	-24.89M	-132.12M	390.00M	-115.55M
Balance Sheet
Total Assets	0.00	1.76B	1.57B	1.52B	1.86B	1.90B
Cash, Cash Equivalents and Short-Term Investments	18.36M	13.63M	62.91M	119.39M	170.59M	76.30M
Total Debt	0.00	391.84M	586.50M	751.02M	1.30B	1.63B
Total Liabilities	-1.04B	726.24M	884.59M	1.06B	1.72B	2.15B
Stockholders Equity	1.04B	1.04B	681.54M	454.41M	133.38M	-257.97M
Cash Flow
Free Cash Flow	0.00	-137.55M	-74.58M	7.67M	717.33M	75.44M
Operating Cash Flow	0.00	18.99M	17.73M	89.53M	792.46M	88.11M
Investing Cash Flow	0.00	-117.96M	-94.88M	73.50M	-61.72M	-1.61M
Financing Cash Flow	0.00	52.92M	19.53M	-216.43M	-631.77M	-117.98M

Lyka Labs Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 94.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LYKALABS, the sentiment is Negative. The current price of 94.4 is below the 20-day moving average (MA) of 95.59, below the 50-day MA of 98.24, and below the 200-day MA of 113.55, indicating a bearish trend. The MACD of -1.12 indicates Negative momentum. The RSI at 44.13 is Neutral, neither overbought nor oversold. The STOCH value of 34.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:LYKALABS.

Lyka Labs Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDICO	66 Neutral	₹4.17B	39.38	―	―	9.81%	20.86%
SMSLIFE	65 Neutral	₹3.39B	19.72	―	0.13%	3.34%	-3.38%
LYKALABS	58 Neutral	₹3.46B	45.09	―	―	19.40%	1286.88%
ZIMLAB	56 Neutral	₹3.32B	35.97	―	―	-3.36%	-47.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NURECA	49 Neutral	₹3.19B	77.53	―	―	43.30%	―
BROOKS	41 Neutral	₹3.57B	279.45	―	―	10.30%	―

Lyka Labs Limited Corporate Events

Lyka Labs Updates on Amalgamation Process

Lyka Labs Limited has provided an update on its ongoing Scheme of Amalgamation, following a directive from the National Company Law Tribunal (NCLT) in Ahmedabad. The Tribunal has instructed the Income Tax Department to submit a reply within 15 days due to a change in counsel, with the next hearing scheduled for November 6, 2025. This development is part of the procedural steps in the amalgamation process, which may impact the company’s strategic operations and stakeholder interests.